Abstract

A culturally tailored virtual program could meet the survivorship needs of Asian American women breast cancer survivors (AABC). This study aims to determine the efficacy of a culturally tailored virtual information and coaching/support program (TICAA) in improving AABC’s survivorship experience. A randomized clinical trial (NCT02803593) was conducted from January 2017 to June 2020 among 199 AABC. The intervention group utilized TICAA and the American Cancer Society [ACS] website while the control group used only ACS website for 12 weeks. The outcomes were measured using the SCNS-34SF (needs; primary), the MSAS-SF (symptoms; secondary), and the FACT-B (quality of life; secondary). The data were analyzed using an intent-to-treat approach. The intervention group showed significant reductions in their needs from the baseline (T0) to post 4 weeks (T1) and to post 12 weeks (T2). Although the changes were not statistically significant, the intervention group had decreased symptoms from T0 to T2 while the control group had an increase in their symptoms. The intervention group had a significant increase in their quality of life from T0 to T2. A culturally tailored virtual program could therefore improve quality of life in AABC patients. Trial Registration: To Enhance Breast Cancer Survivorship of Asian Americans (TICAA), NCT02803593, https://clinicaltrials.gov/ct2/show/NCT02803593?titles=TICAA&draw=2&rank=1

Virtual support methods have been shown to be an effective aid in cancer survivorship. Here, the authors created a culturally tailored information and support system for Asian American breast cancer patients and showed these resources improved quality of life.

Details

Title
A randomized controlled trial testing a virtual program for Asian American women breast cancer survivors
Author
Im, Eun-Ok 1   VIAFID ORCID Logo  ; Chee, Wonshik 1   VIAFID ORCID Logo  ; Paul, Sudeshna 2   VIAFID ORCID Logo  ; Choi, Mi-Young 3 ; Kim, Seo Yun 2   VIAFID ORCID Logo  ; Deatrick, Janet A. 4   VIAFID ORCID Logo  ; Inouye, Jillian 5   VIAFID ORCID Logo  ; Ma, Grace 6 ; Meghani, Salimah 4 ; Nguyen, Giang T. 7   VIAFID ORCID Logo  ; Schapira, Marilyn M. 4 ; Ulrich, Connie M. 4   VIAFID ORCID Logo  ; Yeo, SeonAe 8 ; Bao, Ting 9 ; Shin, David 10 ; Mao, Jun J. 9   VIAFID ORCID Logo 

 The University of Texas at Austin, Austin, USA (GRID:grid.89336.37) (ISNI:0000 0004 1936 9924) 
 Emory University, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502) 
 Emory University, Atlanta, USA (GRID:grid.189967.8) (ISNI:0000 0001 0941 6502); Chungbuk National University, Cheongju-si, South Korea (GRID:grid.254229.a) (ISNI:0000 0000 9611 0917) 
 University of Pennsylvania, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972) 
 University of Hawaii, Honolulu, USA (GRID:grid.162346.4) (ISNI:0000 0001 1482 1895) 
 Temple University, Philadelphia, USA (GRID:grid.264727.2) (ISNI:0000 0001 2248 3398) 
 Harvard University Health Services, Cambridge, USA (GRID:grid.38142.3c) (ISNI:0000 0004 1936 754X) 
 University of North Carolina, Chapel Hill, USA (GRID:grid.410711.2) (ISNI:0000 0001 1034 1720) 
 Memorial Sloan Kettering Cancer Center, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
10  University of California, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718) 
Pages
6475
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2877037533
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.